Filed under
Healthcare
Calm, cited readings on Healthcare, most recent first. Cited, not tips.
SUNPHARMA · Sun Pharmaceutical Industries Limited · BSE · Filed 7 Oct · 1 min
Sun Pharma Board to Weigh NCD Issue of Up to ₹15,000 Crore on 12 October
The drugmaker will consider issuing listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 2 Oct · 1 min
Aurobindo's Apitoria Closes Acquisition of A1 Biochem's Contract Research Business
Wholly owned subsidiary Apitoria Pharma has completed its purchase, taking an 80% stake in A1 Biochem Labs (India) and, through it, the group's US operations.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 2 Oct · 1 min
Aurobindo arm completes US acquisition of A1 Biochem Labs for USD 15.25 million
A1 Biochem USA Inc has acquired 100% of A1 Biochem Labs LLC, a North Carolina contract research and chemistry services firm, in an all-cash deal completed on October 2, 2026.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 1 Oct · 1 min
A1 Biochem Labs no longer wholly owned as former promoter takes 20%
Aurobindo's step-down subsidiary A1 Labs allotted shares and debentures to former promoter Dr. Rajendra Gadikota, leaving Apitoria with 80%.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 1 Oct · 1 min
Jagsonpal Completes Acquisition of Group Pharma's Wellness Portfolio
The company told the exchanges that its Business Transfer Agreement with Group Pharmaceuticals, signed 23 September 2026, was consummated effective 1 October 2026 after conditions precedent were met.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 23 Sept · 1 min
Jagsonpal to acquire Group Pharmaceuticals' Wellness Portfolio via slump sale
The company signed a Business Transfer Agreement to buy the women's-health portfolio on a going-concern basis, with consideration capped at ₹46.7 crore.
YATHARTH · Yatharth Hospital & Trauma Care Services Limited · NSE · Filed 17 Sept · 2 min
Yatharth Hospital board clears preferential issue to Cyprus-based Rasmalai for 24.87% stake
The board approved issuing equity shares and warrants to Rasmalai Limited at ₹985.17 apiece for a 24.87% fully diluted holding with board nomination rights, subject to shareholder and regulatory approval.
YATHARTH · Yatharth Hospital & Trauma Care Services Limited · BSE · Filed 14 Sept · 1 min
Yatharth Hospital Board to Weigh Fund-Raising on 17 September
The hospital operator's board will meet to consider raising capital for growth via debt, a rights issue, preferential allotment, QIP or other securities, per the filing.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 12 Sept · 1 min
Aurobindo Subscribes USD 1 Million to Fully Own New US Research Arm
An Aurobindo step-down subsidiary has fully subscribed the initial share capital of A1 Biochem USA Inc, a newly incorporated US contract research and development company.
INDRAMEDCO · Indraprastha Medical Corporation Limited · NSE · Filed 29 Aug · 1 min
Indraprastha Medical sets 18 September record date for proposed ₹4 dividend
The company fixed Friday, 18 September 2026 as the record date for its FY2025-26 dividend of ₹4 per share, subject to shareholder approval at the 38th AGM.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 14 Aug · 1 min
Aurobindo's Eugia Unit I gets US FDA Warning Letter after OAI status
The Eugia Pharma formulation facility, a subsidiary unit Aurobindo says contributes about 2% of group revenue, has escalated from Official Action Indicated to a Warning Letter, with no impact stated on current US supplies.
INDRAMEDCO · Indraprastha Medical Corporation Limited · NSE · Filed 6 Aug · 1 min
Apollo Delhi operator posts higher Q1 FY27 revenue and profit, sets AGM and dividend record date
Indraprastha Medical reported higher unaudited revenue and profit after tax for the June quarter and set a 24 September AGM with an 18 September dividend record date.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 5 Aug · 2 min
Aurobindo Pharma consolidates Lannett for the first time in Q1 FY27
The quarter ended June 30, 2026 is the first to include newly acquired US business Lannett Company LLC, which the company says makes results non-comparable to prior periods.
AUROPHARMA · Aurobindo Pharma Limited · BSE · Filed 5 Aug · 1 min
Aurobindo Pharma Q1 FY27 revenue up 16.3%, led by Europe and Growth Markets
Aurobindo reported consolidated Q1 FY27 revenue of ₹9,150 crore and net profit of ₹1,032 crore, with growth across formulations and API.
FERMENTA · Fermenta Biotech Limited · BSE · Filed 4 Aug · 1 min
Fermenta Biotech Sets 11 August Board Meeting for Q1 Results
Its board will meet on 11 August 2026 to approve unaudited standalone and consolidated results for the quarter ended 30 June 2026.
FERMENTA · Fermenta Biotech Limited · NSE · Filed 4 Aug · 1 min
Fermenta Biotech Shares Begin Trading on the NSE
Fermenta Biotech's existing equity shares were listed on the National Stock Exchange from 4 August 2026, while retaining their BSE listing — a dual listing, not a new issue.
YATHARTH · Yatharth Hospital & Trauma Care Services Limited · BSE · Filed 4 Aug · 1 min
Yatharth Hospital board to weigh Q1 results, first interim dividend and 2026 ESOP scheme on 10 August
The hospital operator's board meets on 10 August 2026 to consider first-quarter results, a first interim dividend for FY2026-27, and a new employee stock option scheme.
BYKE · The Byke Hospitality Ltd · BSE · Filed 3 Aug · 1 min
Byke Hospitality to Consider Q1 FY27 Results on 10 August
The hotel operator's board meets on 10 August 2026 to approve unaudited results for the quarter ended 30 June 2026 and adopt the auditor's limited review report.
SUNPHARMA · Sun Pharmaceutical Industries Limited · NSE · Filed 31 Jul · 2 min
Sun Pharma Q1 FY27: sales up 10.1%, Organon deal cleared by target's shareholders
Consolidated sales and net profit both rose year-on-year, even as US generics slipped and the pending Organon acquisition began flowing costs through exceptional items.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 29 Jul · 1 min
Jagsonpal Pharmaceuticals sets 4 September record date for ₹4 dividend
Only shareholders on the register as of Friday, 4 September 2026 will qualify for the FY2025-26 dividend, which awaits approval at the 18 September AGM.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 29 Jul · 1 min
Jagsonpal Pharmaceuticals names two internal executives as Senior Management Personnel
Its IT head and its CQA & regulatory affairs head have been designated Senior Management Personnel, effective 29 July 2026.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 29 Jul · 1 min
Jagsonpal lifts Q1 FY27 profit, completes 85% buy of hospital-supplies firm Aequitas
The pharma company reported higher revenue and profit for the quarter ended June 2026 and closed an all-cash 85% acquisition of Aequitas Healthcare, its entry into hospital supplies.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 29 Jul · 2 min
Jagsonpal Q1 FY27 profit rises; discloses Aequitas stake buy and buy-back
The pharma company reported higher year-on-year quarterly net profit and disclosed an 85% stake acquisition and a share buy-back tied to the same period.
INDRAMEDCO · Indraprastha Medical Corporation Limited · BSE · Filed 27 Jul · 1 min
Indraprastha Medical Sets 6 August Board Meeting for Q1 Results
The Apollo hospital operator's board will meet on Thursday, 6 August 2026, to approve unaudited results for the quarter ended 30 June 2026.
SUNPHARMA · Sun Pharmaceutical Industries Limited · NSE · Filed 24 Jul · 1 min
Organon Stockholders Approve Sun Pharma's Proposed Acquisition
Sun Pharma says Organon stockholders have approved the merger under which Organon would become a wholly owned subsidiary of a Sun Pharma unit.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 23 Jul · 2 min
Aurobindo's Apitoria to buy 80% of A1 Biochem's contract-research business at USD 17 mn enterprise value
Aurobindo's wholly owned subsidiary Apitoria Pharma will take majority control of A1 Biochem, a US- and India-based contract research organisation, to build a CRDMO platform alongside its API manufacturing.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · BSE · Filed 22 Jul · 1 min
Jagsonpal Pharmaceuticals sets 29 July board meeting for Q1 results
The board meets on Wednesday, 29 July 2026 to approve unaudited results for the quarter ended 30 June 2026.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 21 Jul · 1 min
Aurobindo's CuraTeQ Biologics clears ANVISA inspection for Hyderabad biosimilars plant
Brazil's health regulator approved the wholly owned subsidiary's Hyderabad facility after a GMP inspection, adding Brazilian and Latin American markets to those the plant can supply.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 17 Jul · 1 min
Jagsonpal Completes Acquisition of 85% Stake in Aequitas Healthcare
The company told the exchanges it has closed its previously announced purchase of an 85% equity stake in Aequitas Healthcare Private Limited.
SUNPHARMA · Sun Pharmaceutical Industries Limited · BSE · Filed 10 Jul · 1 min
Sun Pharma to Report Q1 FY2027 Results on 31 July
The board meets that day to approve unaudited standalone and consolidated results for the quarter ended 30 June 2026.
AUROPHARMA · Aurobindo Pharma Limited · BSE · Filed 10 Jul · 1 min
Aurobindo Pharma incorporates new manufacturing subsidiary in Indonesia
An Indonesian step-down arm has set up PT Auro Pharm Indonesia, a wholly owned entity formed to run manufacturing operations in the country.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 7 Jul · 1 min
Jagsonpal Pharmaceuticals completes majority acquisition, makes Aequitas Healthcare a subsidiary
The company said it has completed the purchase of a 69.77% stake in Aequitas Healthcare Private Limited, part of a proposed 85% acquisition, making Aequitas its subsidiary.
AUROPHARMA · Aurobindo Pharma Limited · BSE · Filed 2 Jul · 1 min
Aurobindo Pharma completes transfer of domestic branded generics business to subsidiary Auropharm
The domestic branded generic formulations business now sits inside wholly owned subsidiary Auropharm Limited, effective 1 July 2026, per the filing.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 30 Jun · 1 min
Aurobindo completes acquisition of US generics firm Lannett
Aurobindo Pharma USA has closed its purchase of Lannett Company, which will now operate as a wholly owned subsidiary after US regulatory clearance.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · NSE · Filed 30 Jun · 1 min
Jagsonpal Promoters Report No Share Encumbrances for FY2025-26
In their annual disclosure under SEBI's Takeover Regulations, Jagsonpal Pharmaceuticals' promoters and promoter group declared that none of their shares were pledged or encumbered as at 31 March 2026.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · BSE · Filed 29 Jun · 1 min
Jagsonpal to Acquire 85% of Hospital Distributor Aequitas Healthcare for ₹20.8 Crore
The gynaecology-and-orthopaedics maker signed a Share Purchase Agreement for a majority stake in a Mumbai company that sells pharmaceutical products to hospitals, funded from internal accruals.
JAGSNPHARM · Jagsonpal Pharmaceuticals Limited · BSE · Filed 29 Jun · 1 min
Jagsonpal to acquire 85% of Aequitas Healthcare, entering the hospital segment
The pharma company will pay ₹20.8 crore from internal accruals for a controlling stake in Mumbai-based Aequitas Healthcare, marking its first move into hospital-channel sales.
AUROPHARMA · Aurobindo Pharma Limited · BSE · Filed 25 Jun · 1 min
Aurobindo Pharma takes 26% stake in Swarnaakshu Solar, signs captive solar power deal
The drugmaker made an initial Rs.52 lakh investment for a 26% stake in Swarnaakshu Solar Power and entered a power purchase agreement for captive solar power under Telangana's captive power policy.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 22 Jun · 1 min
Aurobindo's US arm clears FTC hurdle to acquire Lannett, deal set to close by end-June
Aurobindo Pharma USA has received U.S. Federal Trade Commission approval to proceed with its $250 million acquisition of Pennsylvania-based generic maker Lannett Company.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 19 Jun · 1 min
Aurobindo Pharma Clears US FTC Hurdle for Lannett Acquisition
Aurobindo's US subsidiary has obtained the required US Federal Trade Commission approval to acquire 100% of Lannett Company LLC, with closing anticipated before the end of June.
FERMENTA · Fermenta Biotech Limited · BSE · Filed 16 Jun · 1 min
Fermenta Biotech applies to NSE for direct listing of its equity shares
The company told BSE it has filed an application with the National Stock Exchange seeking approval to list and trade its equity shares via the direct listing route.